Evidence map›Paper›PMID 40702274›Full record

ArticleHepatology international2025

CT-based intratumoral and peritumoral radiomics to predict the treatment response to hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 in high-risk hepatocellular carcinoma cases: a multi-center study.

Zihao Liu, Xinge Li, Yong Huang, Xu Chang, Hong Zhang, Xiaodong Wu, Yanzhao Diao, Fengling He, Junyong Sun, Baomin Feng and 1 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Hepatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Zihao Liu *Department of Interventional Therapy II, Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Shandong First Medical University, Jinan, 250117, Shandong, China.
Xinge Li *Department of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250000, Shandong, China.
Yong HuangDepartment of Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China.
Xu ChangDepartment of Interventional Therapy II, Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Shandong First Medical University, Jinan, 250117, Shandong, China.
Hong ZhangDepartment of Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China.
Xiaodong WuDepartment of Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China.
Yanzhao DiaoSchool of Medicine, The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Jinan University, Guangzhou, 518037, China.
Fengling HeDepartment of Radiology, Caoxian County Hospital, Heze, 274499, Shandong, China.
Junyong SunDepartment of Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China.
Baomin FengDepartment of Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China.
Hexin LiangDepartment of Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China. lhx982707299@163.com.ORCID http://orcid.org/0009-0007-4253-6697

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNoninvasive and precise tools for treatment response estimation in patients with high-risk hepatocellular carcinoma (HCC) who could benefit from hepatic arterial infusion chemotherapy (HAIC) plus lenvatinib and humanized programmed death receptor-1 inhibitors (PD-1) (HAIC-LEN-PD1) are lacking. This study aimed to evaluate the predictive potential of intratumoral and peritumoral radiomics for preoperative treatment response assessment to HAIC-LEN-PD1 in high-risk HCC cases. MATERIALS AND

methodsTotally 630 high-risk HCC cases administered HAIC-LEN-PD1 at three institutions were retrospectively identified and assigned to training, validation and external test sets. Totally 1834 radiomic features were, respectively, obtained from intratumoral and peritumoral regions and radiomics models were established using five classifiers. Based on the optimal model, a nomogram was developed and evaluated using areas under the curves (AUCs), calibration curves and decision curve analysis (DCA). Overall survival (OS) and progression-free survival (PFS) were assessed by Kaplan-Meier curves.

resultsThe Intratumoral + Peritumoral 10 mm (Intra + Peri10) radiomics models were superior to the intratumor models and peritumor models, with AUCs of 0.919 (95%CI 0.889-0.949) in the training set, 0.874 (95%CI 0.812-0.936) in validation set and 0.893 (95%CI 0.839-0.948) in external test sets. The nomogram had good calibration ability and clinical value, with the AUCs of 0.936 (95%CI 0.907-0.965) in the training set, 0.878 (95%CI 0.916-0.940) in validation set and 0.902 (95%CI 0.848-0.957) in external test sets. The Kaplan-Meier analysis showed that high-score patients had significantly shorter OS and PFS than the low-score patients (median OS: 11.7 vs. 29.6 months, the whole set, p < 0.001; median PFS: 6.0 vs. 12.0 months, the whole set, p < 0.001).

conclusionsThe Intra + Peri10 model can effectively predict the treatment response of high-risk HCC cases administered HAIC-LEN-PD1. The nomogram could provide an effective tool to evaluate the treatment response and risk stratification.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularLiver NeoplasmsPhenylurea CompoundsQuinolinesTomography, X-Ray ComputedAdultAgedFemaleHumansInfusions, Intra-ArterialMaleMiddle AgedNomogramsRadiomicsRetrospective StudieslenvatinibPhenylurea CompoundsQuinolinesDecision curve analysesHepatic arterial infusion chemotherapyHigh-risk hepatocellular carcinomaIntratumoral and peritumoralLenvatinibMachine learningNomogramRadiomicsRisk stratificationTreatment response

Identifiers

PMID40702274

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.